Myriad Genetics is celebrating promising results from a study demonstrating the clinical utility of its Prolaris prostate cancer molecular diagnostic test. The Utah company hopes to use the data to win Medicare reimbursement for the test by this June.
Myriad Genetics, long known for its predictive breast cancer tests, said recent clinical data backs up assertions that one of its new diagnostic assays can successfully determine which men will face a recurrence or spread of prostate cancer after radical surgery.
Belgium's MDxHealth has partnered with generics maker Teva Pharmaceuticals to commercialize its ConfirmMDx for prostate cancer and PredictMDx for glioblastoma tests in Israel.
Although recent products have given prostate cancer patients more treatment options, the American Cancer Society still estimates that almost 30,000 men died of the disease last year. This week virtual drug developer Madison Vaccines raised $8 million to further its ambitions to cut that figure.
Once a patient is treated for prostate cancer, close medical monitoring offers an imperfect way to catch potential recurrence or spread of the disease. Researchers believe they've found an easier way to get the job done: a biomarker for a cellular switch.
An invasive biopsy has long been the best way to help doctors definitively diagnose prostate cancer. But Canadian researchers, through their use of a synchrotron particle accelerator, believe they're on the way toward developing a more precise, less-invasive approach.
Texas biotech GenSpera touted successful Phase I data this week for its prodrug candidate designed to target solid tumors by taking advantage of the enzymatic action of the prostate-specific membrane antigen, which effectively "pulls the pin on the grenade" of the uniquely delivered drug.
A three-gene biomarker could be used as a predictor of prostate cancer growth to help doctors identify which patients need earlier treatment.
NxThera has nailed down $18.2 million in new financing and a pivotal CE mark. Execs will put the money and European regulatory approval to use in multiple ways to advance the company's water vapor endourology surgical device as a treatment for various prostate and kidney conditions.
A team at the La Jolla, CA-based Sanford-Burnham Medical Research Institute has developed a compound called SMIP004 that causes a decrease in the number of androgen receptors--proteins located in prostate cancer cells that are activated by testosterone.